Monitor the December 10 vote outcome for equity plan approvals; passage would signal management's ability to refresh equity compensation for retention. The 4.1% combined dilution is moderate but notable given the company's small float and heavy warrant overhang (12.6M shares issuable).
Price Chart
Executive Summary
Aytu BioPharma filed its definitive proxy statement for the 2026 annual meeting, seeking shareholder approval for five proposals: re-election of five incumbent directors, a 500,000-share increase to the 2023 Equity Incentive Plan (doubling its reserve to 1,000,000 shares), adoption of a new 2027 Employee Stock Purchase Plan (reserving 500,000 shares), ratification of Grant Thornton as auditor, and an advisory say-on-pay vote. The filing is routine governance with moderate dilution from equity plan expansion; no financial results or material corporate events are disclosed.
Key Facts
- Annual meeting scheduled for December 10, 2026; record date October 13, 2026.
- Five incumbent directors nominated for re-election; all are independent except CEO Joshua R. Disbrow.
- Proposal to increase 2023 Equity Incentive Plan share reserve by 500,000 shares to a total of 1,000,000 shares.
- Proposal to adopt 2027 Employee Stock Purchase Plan, reserving 500,000 shares (4.6% of outstanding).
- Combined fully-diluted overhang from both equity plans would be 4.1% if both proposals pass.
- As of September 30, 2026, 202,265 stock options outstanding (weighted-average exercise price $4.36) and 2,057 shares available for future grants.
- CEO Joshua R. Disbrow total compensation for FY2026: $844,854 (salary $608,154, stock awards $42,750, bonus $177,000, 401(k) match $16,950).
- FY2026 corporate performance objectives included launching EXXUA, achieving certain EBITDA and net revenue goals; Compensation Committee determined 50% payout of target bonus.
- Audit fees for FY2026 were $705,000, down from $849,000 in FY2025.
- No shareholder proposals or contested director elections noted.
Financial Impact
Equity plan amendments could dilute existing shareholders by up to 4.1% on a fully-diluted basis if both proposals pass. CEO total compensation $844,854 for FY2026.
Risk Factors
- Potential dilution of ~4.1% from equity plan share increases if both proposals pass.
- Heavy warrant overhang: 12.6 million shares issuable upon exercise of outstanding warrants, representing more than 100% of current shares outstanding.
- Company reported net loss of $14.3 million for FY2026, worsening from $13.6 million in FY2025.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001437749-26-033276 |
| Document: 0001437749-26-033276-index-headers.html | 0001437749-26-033276 |
| Document: 0001437749-26-033276-index.html | 0001437749-26-033276 |
| Document: 0001437749-26-033276.txt | 0001437749-26-033276 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | DEF 14A | $1.90 | awaiting T+20 | — | $1.90 (−0.00%) |
Sep 22, 2026 4w ago | 8-K | $2.28 $1.96 | ▼ −14.04% | ▼ −14.72% | $1.90 (−16.67%) |
Jun 25, 2026 17w ago | 8-K | $2.17 $2.16 | ▼ −0.46% | ▼ −1.72% | $1.90 (−12.44%) |
Apr 2, 2026 29w ago | 8-K | $2.66 $2.55 | ▲ +4.14% | ▲ +13.12% | $1.90 (+28.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers